retatrutide triple agonist of

Retatrutide is a novel investigational drug described as a triple agonist of the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Developed by Eli Lilly, it is designed to target multiple metabolic pathways simultaneously, offering a potentially more effective treatment for obesity, type 2 diabetes, and related metabolic conditions. By acting on GLP-1 and GIP receptors, retatrutide enhances insulin secretion, reduces appetite, and slows gastric emptying, leading to improved blood glucose control and significant weight loss. The activation of the glucagon receptor increases energy expenditure, further supporting weight reduction. Clinical trials have shown that retatrutide can lead to dramatic weight loss—over 24% in some patients—making it one of the most promising anti-obesity drugs currently in development. Its triple-agonist mechanism represents a new frontier in metabolic medicine, offering hope for more comprehensive and lasting treatment outcomes for people struggling with obesity and metabolic syndrome.